Skip to content

A phase-II study of a modified Hyper-CVAD frontline therapy for patients with poor prognosis diffuse large B-cell and peripheral T-cell non-Hodgkins lymphoma to evaluate safety and improve remission rate.

A phase-II study of a modified Hyper-CVAD frontline therapy for patients with poor prognosis diffuse large B-cell and peripheral T-cell non-Hodgkins lymphoma to evaluate safety and improve remission rate.

Status
Completed
Phases
Phase 2
Study type
Interventional
Source
ANZCTR
Registry ID
ACTRN12605000105640
Enrollment
69
Registered
2005-08-09
Start date
2001-09-07
Completion date
2008-01-09
Last updated
2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

A dose and time intensive chemotherapy regimen comprising alternating A and B cycles. A cycles comprise hyperfractionate cyclophosphamide, vincristine, doxorubicin and dexamethasone, and B cycles comprise high-dose methotrexate and high-dose cytosine arabinoside. A total of 6 cycles are to be delivered.

Sponsors

Australasian Leukaemia and Lymphoma Group
Lead SponsorOther Collaborative groups

Study design

Allocation
Non-randomised trial
Intervention model
Single group
Primary purpose
Treatment
Masking
Open (masking not used)

Eligibility

Sex/Gender
All
Age
15 Years to 70 Years
Healthy volunteers
No

Inclusion criteria

(1)Patients with previously untreated mature (post-thymic) T-cell or NK-cell NHL and an IPI score of greater than or equal to 2 OR Patients with previously untreated diffuse large B-cell NHL (2)ECOG performance status 0 to 3 inclusive.(3)A serum creatinine of less than or equal to 0.15 mmol/L. Adequate hepatic function (bilirubin less than or equal to 2.5 x ULN), and haemopoietic indices (haemoglobin greater than or equal to 90, absolute neutrophil count greater than or equal to 1.0, platelets greater than or equal to 100), unless due to lymphomatous infiltration.(4)Seronegativity for antibodies to HIV (see 7.6)(5)Normal left ventricular ejection fraction, according to institutional criteria.(6)Written informed consent

Exclusion criteria

(1)Prior diagnosis of "low-grade" NHL, although patients with discordant bone marrow histology (i.e. small cell lymphomatous infiltrate of marrow) are eligible.(2)Prior treatment for NHL.(3)Past history of serious cardiac, pulmonary, hepatic or renal disease, (4)A past history of cancer (other than non-melanoma skin cancer or carcinoma of the cervix in situ).(5)Contraindication to the use of the study drugs, including known sensitivity to E. Coli derived preparations. This includes agreement to use a medically acceptable and effective means of contraception throughout the treatment period for both male and female patients of childbearing potential.(6)Pregnant women or breast-feeding mothers. History of solid-organ transplantation.

Outcome results

None listed

Source: ANZCTR · Data processed: Feb 22, 2026